Development of responder definitions for fibromyalgia clinical trials
about
Interpreting effect sizes and clinical relevance of pharmacological interventions for fibromyalgia.Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study.Effect of transcutaneous electrical nerve stimulation on pain, function, and quality of life in fibromyalgia: a double-blind randomized clinical trial.Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.A pilot study of health and wellness coaching for fibromyalgia.Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ).A New Rehabilitation Tool in Fibromyalgia: The Effects of Perceptive Rehabilitation on Pain and Function in a Clinical Randomized Controlled Trial.Patient-Reported Outcomes and Fibromyalgia.The PROMIS FatigueFM Profile: a self-report measure of fatigue for use in fibromyalgia.Cognitive impairment in fibromyalgia.Recent strategies for drug development in fibromyalgia syndrome.A meta-analysis to determine the effect of pharmacological and non-pharmacological treatments on fibromyalgia symptoms comprising OMERACT-10 response criteria.Challenges of implementing fibromyalgia treatment guidelines in current clinical practice.The effects of long- and short-term interdisciplinary treatment approaches in women with fibromyalgia: a randomized controlled trial.Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.Longitudinal stability of fibromyalgia symptom clusters.
P2860
Q33938142-837F4349-71AC-47B1-9474-3F80BB020C9BQ34035333-325B078D-3E7F-403F-B5A8-7E22BD7DA3F4Q34584386-1E9CE4FE-355C-4AA1-9C20-F35579C4B740Q34965703-7D31EAE7-BECD-4307-8034-975606384CB7Q35780920-D27EB828-F976-4FD3-A812-4BD5F2F471BCQ36184906-6813D700-9F32-47A0-8E59-6B66152ECCDFQ36480034-872E0F41-6D25-41A9-983D-86CBB01FAAFBQ36537166-282E2AA3-F6A4-47F1-A47C-EC6E1A5CC774Q36859735-3957D676-6944-42FC-AF15-A4EB40AD48F7Q36971094-63EBD999-4A80-4738-B212-B456A44D999BQ38109575-0D8AA583-9FD0-46B8-A89E-19194E9BA976Q38881756-80A00436-C6E9-4B7F-8557-469A167DF9A9Q39179219-A5019226-4DFC-49DF-81AB-B16E0A4F33A2Q39340760-5540CF97-AB05-4499-8B20-C84D897CCCEFQ47778944-9626B477-5739-4420-86D4-CA8A6DC58609Q52681690-F8A38932-9926-4092-8D0C-CCDBB657FA65Q52682704-24755004-E156-48C6-88A9-13386581A0BC
P2860
Development of responder definitions for fibromyalgia clinical trials
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Development of responder definitions for fibromyalgia clinical trials
@ast
Development of responder definitions for fibromyalgia clinical trials
@en
type
label
Development of responder definitions for fibromyalgia clinical trials
@ast
Development of responder definitions for fibromyalgia clinical trials
@en
prefLabel
Development of responder definitions for fibromyalgia clinical trials
@ast
Development of responder definitions for fibromyalgia clinical trials
@en
P2093
P2860
P356
P1476
Development of responder definitions for fibromyalgia clinical trials
@en
P2093
Birol Emir
Chinglin Lai
David A Williams
Fujun Wang
James I Hudson
Leslie J Crofford
Philip J Mease
Rong Zablocki
Susan A Martin
P2860
P304
P356
10.1002/ART.33360
P577
2012-03-01T00:00:00Z